Search
Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.
Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.
The European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO
The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).
Read moreFaculty details
Welcome to the faculty details page. On this page you can find instructions for the speakers and chairs of the congress:
You can download the PowerPoint Template here. If you use your own template, please use a 16x9 format.
Lymphoma, multiple myeloma and marrow failure syndromes better understood during Sri Lanka tutorial
Hematologists from Sri Lanka and surrounding countries learned how to best care for patients with lymphoma, multiple myeloma and bone marrow failure syndromes and stem cell transplantation during the joint Tutorial organized by EHA with the Sri Lanka College of…
Read moreGdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.
EHA and EBMT joint meeting on CAR T cells, first of its kind in Europe
The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.
Read moreIbrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.
Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.
Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013
In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.
Read moreTARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS
Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.
Read moreHighlights from the SWG
SWG Session at EHA2023ELN-EHA SWG for CML: CML: modelling the futureChairJane Apperley (United Kingdom)
Topics and presenters
Identifying new targets for BCR::ABL1 inhibition: Oliver Hantschel (Germany). Dissecting phylogenetic trees in CML: Aleksandra Kamizela (United Kingdom).
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- »